---
schema_version: "secwatch.filing_event.v1"
accession: "0001549595-25-000105"
form_type: "8-K"
ticker: "NRIX"
cik: "0001549595"
company_name: "Nurix Therapeutics, Inc."
filed_at: "2025-08-22T23:59:59+00:00"
generated_at: "2026-05-17T10:33:32.261201+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.2
calibrated_materiality_score: 0.2
confidence: "high"
source: SEC EDGAR
---

# Nurix director Lori Kunkel resigns; Roy Baynes named committee chair

## Summary
- Director Lori A. Kunkel, M.D. resigns from Board and committees effective September 1, 2025.
- Resignation not due to any disagreement with company on operations, policies, or practices.
- Board appoints Roy D. Baynes, MB.Bch., M.Med., Ph.D., as chair of Clinical and Commercialization Committee.

## SEC filing metadata
- accession: 0001549595-25-000105
- form_type: 8-K
- ticker: NRIX
- cik: 0001549595
- company_name: Nurix Therapeutics, Inc.
- filed_at: 2025-08-22T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.2
- calibrated_materiality_score: 0.2
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1549595/000154959525000105/0001549595-25-000105-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1549595/000154959525000105/nrix-20250819.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001549595-25-000105
- JSON: https://secwatch.observer/filing/0001549595-25-000105.json
- Plain text: https://secwatch.observer/filing/0001549595-25-000105.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.